Publications

Evolution of an integron carrying blaVIM-2 in Central Europe: Report from the SENTRY Antimicrobial Surveillance Program. Abstr. P717. by Toleman MA, Hryniewicz W, Bennett P, Jones RN and Walsh TR published in Clin Microbiol Infect 2003; 9 (Suppl 1): 156

Actividad in vitro comparativa de garenoxacino (BMS-284756). Programa SENTRY Espana (1999-2000). by Loza E, Canton R, Pascual A, Tubau F, Morosini MI, Almaraz F, Perea E, Martin R and Jones RN published in Enferm. Infecc. Microbiol. Clin. 2003; 21 (8):404-409

Prevalence and resistance rates of Enterobacter spp. in nosocomial infections, Euro-SENTRY Antimicrobial Surveillance Program, 1997 – 2001. Abstr. P714. by Rodriguez-Villalobos H, Struelens MJ and Jones RN on Behalf of the Euro-SENTRY Participants published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): 155

Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001). by Sader HS, Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2003; 47 (1): 361-364

Cloning of a hybrid metallo-beta-lactamase gene conferring a novel IMP variant blaIMP-13 in Pseudomonas aeruginosa in Italy: Report from the SENTRY Antimicrobial Surveillance Program by Toleman MA, Jones RN, Walsh TR published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): 119

Pathogen occurrence and antimicrobial resistance trends among urinary tract infection isolates in the Asia-Western Pacific region: Report from the SENTRY Antimicrobial Surveillance Program, 1998-1999. by Turnidge J, Bell J, Biedenbach DJ and Jones RN published in Int. J. Antimicrob. Agents 2002; 20 (1): 10-17

Prevalence of extended spectrum β-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: Regional results from SENTRY Antimicrobial Surveillance Program (1998-99). by Bell JM, Turnidge JD, Gales AC, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 42 (3): 193-198

Molecular characterization of SPM-1, a novel metallo-beta-lactamase isolated in Latin America: Report from the SENTRY Antimicrobial Surveillance Programme. by Toleman MA, Simm AM, Murphy TA, Gales AC, Biedenbach DJ, Jones RN and Walsh TR published in J. Antimicrob. Chemother. 2002; 50 (5): 673-679

Impact of modified nonmeningeal Streptococcus pneumoniae interpretive criteria (NCCLS M100-S12) on the susceptibility patterns of five parenteral cephalosporins: Report from the SENTRY Antimicrobial Surveillance Program (1997 to 2001). by Jones RN, Mutnick AH and Varnam DJ published in J. Clin. Microbiol. 2002; 40 (11): 4332-4333

In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY Antimicrobial Surveillance Program (1998-1999). by Bell JM, Turnidge JD, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 43 (4): 315-318

Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: Report from the SENTRY Antimicrobial Surveillance Program (2000). by Kirby JT, Mutnick AH, Jones RN, Biedenbach DJ, Pfaller MA and The SENTRY Participants Group published in Diagn. Microbiol. Infect. Dis. 2002; 43 (4): 303-309

Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: Summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000). by Jones RN, Kirby JT, Beach ML, Biedenbach DJ and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2002; 43 (3): 239-243

Antimicrobial susceptibilities of H. influenzae and M. catarrhalis causing lower respiratory tract infections: SENTRY Antimicrobial Surveillance Program, Europe 2000. Abstr. P1109. by Loza E, Canton R, Morosini MI, Jones RN, Baquero F and The SENTRY Participants Group published in Clin. Microbiol. Infect. 2002; 8 (Suppl 1):250-251

Epidemiology of antibiotic resistance of bacterial pathogens from intensive care units: The SENTRY Surveillance Program in Europe 2000. by Rodriguez-Villalobos H, Jones RN, Struelens MJ published in Clin. Microbiol. Infect. 2002; 8 (Suppl 1):196-197

Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: Report from the SENTRY Antimicrobial Surveillance Program (1998-1999) including an in vitro evaluation of BMS284756. by Bell J, Turnidge J, Jones RN and SENTRY Regional Participants Group published in Int. J. Antimicrob. Agents 2002; 19 (2): 125-132

Antimicrobial susceptibility patterns of Beta-hemolytic and viridans group streptococci: Report from the SENTRY Antimicrobial Surveillance Program (1997-2000). by Gordon KA, Beach ML, Biedenbach DJ, Jones RN, Rhomberg PR and Mutnick AH published in Diagn. Microbiol. Infect. Dis. 2002; 43 (2): 157-162

Spectrum and potency evaluation of a new oxazolidinone, linezolid: Report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. by Mutnick AH, Biedenbach DJ, Turnidge JD and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 43 (1): 65-73

Antimicrobial activity of broad-spectrum agents tested against Gram-negative bacilli resistant to ceftazidime: Report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). by Jones RN, Varnam DJ published in Diagn. Microbiol. Infect. Dis. 2002; 44 (4): 379-382

Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. by Pfaller MA, Diekema DJ, Jones RN, Messer SA and Hollis RJ published in J. Clin. Microbiol. 2002; 40 (3): 852-856

Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from blood stream infections in Latin American medical centers. by Sader HS, Jones RN, Andrade-Baiocchi S, Biedenbach DJ and The SENTRY Participants Group (Latin America) published in Diagn. Microbiol. Infect. Dis. 2002; 44 (3): 273-280

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000. by Pfaller MA, Messer SA, Hollis RJ and Jones RN published in Antimicrob. Agents Chemother. 2002; 46 (4): 1032-1037

Skin and soft tissue infections in Latin American medical centers: Four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns. by Sader HS, Jones RN, Silva JB and The SENTRY Participants Group (Latin America) published in Diagn. Microbiol. Infect. Dis. 2002; 44:281-288

Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: Report from the SENTRY Antimicrobial Surveillance Program. by Jones RN, Della-Latta P, Lee LV and Biedenbach DJ published in Diagn. Microbiol. Infect. Dis. 2002; 42 (2): 137-139

Urinary tract infection trends in Latin American hospitals: Report from the SENTRY Antimicrobial Surveillance Program (1997-2000). by Gales AC, Sader HS, Jones RN and The SENTRY Participants Group (Latin America) published in Diagn. Microbiol. Infect. Dis. 2002; 44 (3): 289-299

BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Programme (2000). by Gordon KA, Pfaller MA and Jones RN. published in J. Antimicrob. Chemother. 2002; 49 (5): 851-855

Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: Frequency of occurrence and antimicrobial susceptibility profile: Results from the SENTRY Antimicrobial Surveillance Program (1997-2000). by Gales AC, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 44 (3): 301-311

Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): Correlations of results from disk diffusion, Etest and reference dilution methods. by Deshpande LM, Fix AM, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 42 (4): 283-290

Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: Geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). by Gales AC, Jones RN, Forward KR, Linares J, Sader HS and Verhoef J published in Clin. Infect. Dis. 2001; 32 (Suppl 2): S104-S113

Pathogen frequency and resistance patterns in Brazilian hospitals: Summary of results from three years of the SENTRY Antimicrobial Surveillance Program. by Sader HS, Gales AC, Pfaller MA, Mendes RE, Zoccoli C, Barth A and Jones RN published in Braz. J. Infect. Dis. 2001; 5 (4): 200-214

Characterization of Pseudomonas aeruginosa isolates: Occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. by Gales AC, Jones RN, Turnidge J, Rennie R and Ramphal R published in Clin. Infect. Dis. 2001; 32 (Suppl 2): S146-S155

Neisseria meningitidis with decreased susceptibility to penicillin: Report from the SENTRY antimicrobial surveillance program, North America, 1998-99. by Richter SS, Gordon KA, Rhomberg PR, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 41 (1-2): 83-88

Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997- 1999. by Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN and Beach M published in Clin. Infect. Dis. 2001; 32 (Suppl 2): S114-S132

International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. by Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ and Messer SA published in J. Clin. Microbiol. 2001; 39 (9): 3254-3259

Accuracy of broth microdilution and Etest methods for detecting chloramphenicol acetyl transferase mediated resistance in Streptococcus pneumoniae: Geographic variations in the prevalence of resistance in The SENTRY Antimicrobial Surveillance Program (1999). by Deshpande LM, Jones RN and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2001; 39 (4): 267-269

Antibacterial activity of 41 antimicrobials tested against over 2,773 bacterial isolates from hospitalized patients with pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (North America, 1998). by Mathai D, Lewis MT, Kugler KC, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 39 (2): 105-116

Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from the SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States. by Biedenbach DJ, Jones RN and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2001; 39 (4): 245-250

Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: A report from the SENTRY Antimicrobial Surveillance Program (North America). by Mathai D, Jones RN and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2001; 40 (3): 129-136

Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: Results from the SENTRY Antimicrobial Surveillance Program, 1997-1999. by Low DE, Keller N, Barth A and Jones RN published in Clin. Infect. Dis. 2001; 32 (Suppl 2): S133-S145

Geographic variations in BMS284756 activity against pathogens associated with skin and soft tissue Infections: Report from the SENTRY Antimicrobial Surveillance Program (2000). Abstr. P35. by Kirby JT, Biedenbach DJ, Pfaller MA, Jones RN, and SENTRY Participants Group. published in J. Antimicrob. Chemother. 2001; 47 (Suppl 2): 25

BMS-284756 activity and spectrum tested against pathogens isolated in the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program (1999). Abstr P26. by Jones RN published in J. Antimicrob. Chemother. 2001; 47(Suppl 1): 23

Comparative activity of gatifloxacin against S. pneumoniae, H. influenzae, and M. catarrhalis before (1997-99) and during (2000) the clinical release in North America (NA): A SENTRY Antimicrobial Surveillance Program Report, abstr P7. by Jones RN, Pfaller MA, and the SENTRY Participants Group. published in J. Antimicrob. Chemother. 2001; 47 (Suppl S2): 18

Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin? Report from The SENTRY Antimicrobial Surveillance Program (1997-99). by Jones RN and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2001; 39: 237-243

Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): More alike than different! by Jones RN, Beach ML and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2001; 41 (3): 161-163

Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. by Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M and Jones RN. published in Clin. Infect. Dis. 2001; 32 (Suppl 2): S81-S93

BMS284756 potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (2000). Abstr P40. by Gordon KA, Pfaller MA, Jones RN, Sader HS, Biedenbach DJ, Beach ML and the SENTRY Participants Group. published in J. Antimicrob. Chemother. 2001; 47 (Suppl 1): S26-S27

Antimicrobial susceptibility testing of clinical isolates of Bordetella pertussis from northern California: Report from the SENTRY Antimicrobial Surveillance Program. by Gordon KA, Fusco J, Biedenbach DJ, Pfaller MA and Jones RN. published in Antimicrob. Agents Chemother. 2001; 45 (12): 3599-3600

Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY Antimicrobial Surveillance Program medical centers in Latin America (1999). by Gales A, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2001; 45 (5): 1463-1466

Potencies of newer fluoroquinolones against viridans group streptococci isolated in 637 cases of bloodstream infection in the SENTRY Antimicrobial Surveillance Program (1997 to 1999): Beyond Canada! by Jones RN and Pfaller MA published in Antimicrob. Agents Chemother. 2000; 44 (10): 2922-2923

Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: Report from the second year of the SENTRY Antimicrobial Surveillance Program (1998). by Gales AC, Jones RN, Gordon KA, Sader HS, Wilke WW, Beach ML, Pfaller MA and Doern GV published in J. Antimicrob. Chemother. 2000; 45 (3): 295-303

Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 1997-98. SENTRY Study Group. by Gales AC, Jones RN, Pfaller MA, Gordon KA and Sader HS published in Int. J. Infect. Dis. 2000; 4 (2): 75-84